Suppr超能文献

相似文献

2
Destabilizing domains mediate reversible transgene expression in the brain.
PLoS One. 2012;7(9):e46269. doi: 10.1371/journal.pone.0046269. Epub 2012 Sep 28.
3
GDNF-secreting mesenchymal stem cells provide localized neuroprotection in an inflammation-driven rat model of Parkinson's disease.
Neuroscience. 2015 Sep 10;303:402-11. doi: 10.1016/j.neuroscience.2015.07.014. Epub 2015 Jul 10.
4
Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease.
Neurobiol Dis. 2014 May;65:35-42. doi: 10.1016/j.nbd.2014.01.009. Epub 2014 Jan 15.
6
A drug-tunable Flt23k gene therapy for controlled intervention in retinal neovascularization.
Angiogenesis. 2021 Feb;24(1):97-110. doi: 10.1007/s10456-020-09745-7. Epub 2020 Sep 15.
7
Intrastriatal GDNF gene transfer by inducible lentivirus vectors protects dopaminergic neurons in a rat model of parkinsonism.
Exp Neurol. 2014 Nov;261:87-96. doi: 10.1016/j.expneurol.2014.06.022. Epub 2014 Jul 2.

引用本文的文献

1
A systematic screening assay identifies efficient small guide RNAs for CRISPR activation.
Front Bioeng Biotechnol. 2025 Jan 23;13:1336313. doi: 10.3389/fbioe.2025.1336313. eCollection 2025.
2
Oxidative stress induced by sustained supraphysiological intrastriatal GDNF delivery is prevented by dose regulation.
Mol Ther Methods Clin Dev. 2023 Sep 9;31:101106. doi: 10.1016/j.omtm.2023.09.002. eCollection 2023 Dec 14.
3
Development of a New DHFR-Based Destabilizing Domain with Enhanced Basal Turnover and Applicability in Mammalian Systems.
ACS Chem Biol. 2022 Oct 21;17(10):2877-2889. doi: 10.1021/acschembio.2c00518. Epub 2022 Sep 19.
5
Gene-Based Therapeutics for Parkinson's Disease.
Biomedicines. 2022 Jul 26;10(8):1790. doi: 10.3390/biomedicines10081790.
6
Utility of the DHFR-based destabilizing domain across mouse models of retinal degeneration and aging.
iScience. 2022 Apr 6;25(5):104206. doi: 10.1016/j.isci.2022.104206. eCollection 2022 May 20.
8
Gene Therapy Approach with an Emphasis on Growth Factors: Theoretical and Clinical Outcomes in Neurodegenerative Diseases.
Mol Neurobiol. 2022 Jan;59(1):191-233. doi: 10.1007/s12035-021-02555-y. Epub 2021 Oct 15.
9
Development and Validation of CRISPR Activator Systems for Overexpression of CB1 Receptors in Neurons.
Front Mol Neurosci. 2020 Sep 8;13:168. doi: 10.3389/fnmol.2020.00168. eCollection 2020.
10
Regional Differences in Penetration of the Protein Stabilizer Trimethoprim (TMP) in the Rat Central Nervous System.
Front Mol Neurosci. 2020 Sep 3;13:167. doi: 10.3389/fnmol.2020.00167. eCollection 2020.

本文引用的文献

1
FACS binding assay for analysing GDNF interactions.
J Neurosci Methods. 2013 Aug 15;218(1):25-8. doi: 10.1016/j.jneumeth.2013.04.006. Epub 2013 May 10.
2
α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons.
Sci Transl Med. 2012 Dec 5;4(163):163ra156. doi: 10.1126/scitranslmed.3004676.
3
Novel disease-specific promoters for use in gene therapy for Parkinson's disease.
Neurosci Lett. 2012 Nov 14;530(1):29-34. doi: 10.1016/j.neulet.2012.09.059. Epub 2012 Oct 12.
4
Destabilizing domains mediate reversible transgene expression in the brain.
PLoS One. 2012;7(9):e46269. doi: 10.1371/journal.pone.0046269. Epub 2012 Sep 28.
5
Intracellular context affects levels of a chemically dependent destabilizing domain.
PLoS One. 2012;7(9):e43297. doi: 10.1371/journal.pone.0043297. Epub 2012 Sep 12.
6
Regulated protein expression for in vivo gene therapy for neurological disorders: progress, strategies, and issues.
Neurobiol Dis. 2012 Nov;48(2):212-21. doi: 10.1016/j.nbd.2012.03.001. Epub 2012 Mar 9.
9
SignalP 4.0: discriminating signal peptides from transmembrane regions.
Nat Methods. 2011 Sep 29;8(10):785-6. doi: 10.1038/nmeth.1701.
10
Is GDNF beneficial in Parkinson disease?
Nat Rev Neurol. 2011 Sep 20;7(11):600-2. doi: 10.1038/nrneurol.2011.149.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验